Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
出版年份 2017 全文链接
标题
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
作者
关键词
-
出版物
Blood Cancer Journal
Volume 7, Issue 9, Pages e603
出版商
Springer Nature
发表日期
2017-09-08
DOI
10.1038/bcj.2017.85
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- CD30 Expression by B and T Cells
- (2016) Arantza Onaindia et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding
- (2016) Rami N Al-Rohil et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
- (2016) Nancy L. Bartlett et al. LEUKEMIA & LYMPHOMA
- Superior Therapeutic Index in Lymphoma Therapy: CD30 + CD34 + Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack
- (2016) Andreas A Hombach et al. MOLECULAR THERAPY
- Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer
- (2016) Ailin Falkmo Hansen et al. Oncotarget
- The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- B positive feedback loop in peripheral T-cell lymphoma
- (2015) R. L. Boddicker et al. BLOOD
- Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis
- (2015) Katharina Blatt et al. BLOOD
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
- (2015) E. D. Jacobsen et al. BLOOD
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
- (2015) Youn H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
- (2015) Madeleine Duvic et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
- (2014) C. Bossard et al. BLOOD
- Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
- (2014) M. D. Gandhi et al. BLOOD
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
- (2014) S. M. Horwitz et al. BLOOD
- Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project
- (2014) Kenneth R. Carson et al. CANCER
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
- (2014) Michelle A. Fanale et al. JOURNAL OF CLINICAL ONCOLOGY
- Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
- (2014) Nancy L Bartlett et al. Journal of Hematology & Oncology
- Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities
- (2014) Wook Youn Kim et al. LEUKEMIA & LYMPHOMA
- Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
- (2014) P. Muller et al. Cancer Immunology Research
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure
- (2012) Nitya Nathwani et al. LEUKEMIA & LYMPHOMA
- EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation
- (2012) Santiago Montes-Moreno et al. MODERN PATHOLOGY
- Targeted Repression of Overexpressed CD30 Downregulates NF-κB and ERK1/2 Pathway in Hodgkin Lymphoma Cell Lines
- (2012) Mariko Watanabe et al. ONCOLOGY RESEARCH
- Distinct Motifs in the Intracellular Domain of Human CD30 Differentially Activate Canonical and Alternative Transcription Factor NF-κB Signaling
- (2012) Sarah L. Buchan et al. PLoS One
- Ets-1 Activates Overexpression of JunB and CD30 in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
- (2011) Mariko Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
- (2010) Donatella Aldinucci et al. JOURNAL OF PATHOLOGY
- Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis
- (2010) Karl Sotlar et al. MODERN PATHOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma
- (2010) M. Dietlein et al. NUKLEARMEDIZIN-NUCLEAR MEDICINE
- Solution of the Structure of the TNF-TNFR2 Complex
- (2010) Y. Mukai et al. Science Signaling
- CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides
- (2009) James T. Edinger et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo
- (2009) Naoyoshi Maeda et al. CANCER SCIENCE
- A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
- (2009) M. Duvic et al. CLINICAL CANCER RESEARCH
- IRF4 Gene Rearrangements Define a Subgroup of CD30-Positive Cutaneous T-Cell Lymphoma: A Study of 54 Cases
- (2009) Anne Pham-Ledard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells
- (2008) Burkhard Hirsch et al. AMERICAN JOURNAL OF PATHOLOGY
- ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
- (2008) K. J. Savage et al. BLOOD
- Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
- (2008) Ezogelin Oflazoglu et al. BRITISH JOURNAL OF HAEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started